⭐⭐⭐⭐⭐ 5 star review from Symone:
“I Love It – I’m starting to get into vaping and figured I would test out this e-hookah and I love it. It’s very smooth and gives off nice size clouds. I’ll definitely be buying more.”
Some 20 percent or 50 million Americans suffer from arthritis, and many of them are now turning to vaping cannabis products to help manage the associated chronic pain. Some people use marijuana to supplement their current medications while others are eliminating their dependence of prescription painkillers entirely.
While there are very few U.S. peer-reviewed studies on the use of cannabis for arthritis pain relief, there is evidence that the endocannabinoid system found in most mammals, including humans, responds extremely well to the THC in marijuana products. A recent article published in Arthritis Today even seems to endorse cannabis while boasting of its perceived anti-inflammatory properties.
Related Article: The medicinal benefits of vaping CBD for heart disease prevention
Due to the lack of abundance in qualitative scientific research currently available, the article also references four different randomized clinical trials involving placebos. In 2011, the British Journal of Clinical Pharmacology also reviewed another 18 similar projects and determined that smoked, vaped, topically applied, edible, and even synthetic marijuana strains have shown to provide measurable pain relief without measurable negative side effects.
One of the drawbacks (or benefits, depending on one’s point of view) is that smoking or vaping marijuana can sometimes leave the patient feeling a bit euphoric. Since many cannabis strains are psychotropic in nature, many patients are now turning to CBD or Cannabidiol as a more user-friendly alternative without the often-associated high.
Not all rheumatologists are confident in the perceived pain relief and anti-inflammatory benefits that proponents of marijuana and CBD tend to claim. Many physicians are simply remaining open-minded until more U.S. research takes place. However, one study currently being conducted in Canada is already attracting some rather positive attention from within the U.S. medical community, and the study will not even be complete until 2019.
The CAPRI study (Cannabinoid Profile Investigation of Vapourized Cannabis in Patients with Osteoarthritis of the Knee) is designed to measure and compare six different cannabis strains consumed through vaping. The researchers will be evaluating their varying THC dosages and profiles for their associated pain relief benefits or disadvantages in patients suffering from osteoarthritis of the knee.
The study is being funded by the Canadian biopharmaceutical company Prairie Plant Systems (Canada recently became the second nation in the world to legalize marijuana at the federal level. Uruguay was the first). The research team conducting the CAPRI research will include a highly respected group of scientists from McGill University, Dalhousie University, and a competing pharmaceutical company Algorithme Pharma.
Related Article: Did you know that vaping CBD may help eczema sufferers?
from VAPES – VAPES News Blog http://bit.ly/2CdS4ps
⭐⭐⭐⭐⭐ 5 star review from Kizmyaz:
“Very Happy – I love this product ..the day it shipped ..the same day i got it! I was shocked..i will def be ordering all my stuff thru Vapes.com.
As for my Vape..it came package nicely and works great! I love everything about Vapes.com no complaints…HAPPY CUSTOMER 100% …Thank you!”
FDA Chief Gottlieb says he has “unpublished preliminary data” proving a 75% rise in teen vaping for the past year. Dr. Farsalinos calls BULLSHIT!
Scott Gottlieb #vapeban #teenvaping #FDAvapeban #vaping #vapes #vapescom #vape #ecig #ecigs #vapor #propyleneglycol #vapeon #vapenation #vapedaily #vapefamily #vapefam #vapelife #vapelyfe #zamplebox
from VAPES http://bit.ly/2IOR8cq
In a September 12 press release by the U.S. Food and Drug Administration (FDA), its chief makes the very bold and as-yet unproven claim that teen vaping has allegedly risen to epidemic proportions. In a series of mainstream press articles published on the same day, the Chicago Tribune refers to unpublished preliminary data that allegedly indicates a 75 percent rise in teen e-cigarette use within the past year.
“What prompted Gottlieb’s sudden call to arms? One possibility is new statistics that show an alarming rise in vaping. The FDA has unpublished preliminary data that shows a 75 percent increase in e-cigarette use among high school students this year compared with 2017, The Washington Post reports. ‘We cannot allow a whole new generation to become addicted to nicotine,’ Gottlieb said.”
What is this unpublished preliminary data? Who compiled it? What criteria was used to evaluate its contents? Why is the alleged data deemed “preliminary?” And perhaps most importantly, why is the FDA’s data still “unpublished?” These are just a few questions that world-renowned scientist, cardiologist, and e-cig advocate Dr. Konstantinos E Farsalinos wants immediately answered.
“It is extremely important to see detailed data on the ‘epidemic’ declared by the FDA. I emphasize that published data SHOULD include frequency of use and smoking status of e-cigarette users – and of course the prevalence of tobacco cigarette use. Everyone knows that ever e-cigarette use (experimental vaping but not daily use) is simply meaningless. Current e-cigarette use is also for the most part meaningless because (until now) most of never-smoking current e-cigarette users use them for 1-2 days of the past 30 days. However, until we see the data, I will assume that every pattern of e-cigarette use (ever and current use) has increased by 3-fold (200% instead of the reported 75%) compared to 2015. This is how the use of e-cigarettes in the past 30-days by never smoking adolescents would look like (I will not mention ever use because it is a waste of time).”
To label teen vaping as an “epidemic,” the FDA must – at the very least- provide documented evidence that supports these claims. Furthermore, the related statistics must be compiled, evaluated, and presented in a way that uses good, old-fashioned common sense. Dr. Farsalinos is suggesting that the unpublished preliminary data may be grossly inaccurate, especially if its evaluators did not differentiate between experimental teenage use and daily teenage use.
So many of the prior published reports by both the FDA and the U.S. Centers for Disease Control and Prevention (CDC) do not follow this simple principle. Instead, their basis for analysis when interviewing thousands of middle and high school students across the country is to ask a very simplistic question: Have you used an e-cigarette within the past 30-days?
Teenagers experiment. They always have. For generations upon generations, teenagers have always rebelled against their parents in their adolescent impatience to enter adulthood. They perhaps change their style of dress, experiment with makeup, and occasionally miss their curfew every now and again. They push conventional boundaries. And for decades, typical teens have also experimented with booze, marijuana, sex, and of course smoking.
But experimentation does not a daily user make. If a teen experiments with alcohol by drinking a beer or two at a weekend party, does that automatically make him or her an alcoholic? Should alcohol then be over-regulated by the FDA to include only a few flavors of beer and wine? America tried something like that in 1919 with the passage of the Eighteenth Amendment making alcohol illegal in the United States. It didn’t work, by the way. 14-years later, the Twenty-first Amendment lifted the alcohol ban forever.
If a teenager smokes a doobie at a party, does that automatically make him or her a marijuana addict? Should the FDA over-regulate marijuana out of existence, as well? Apparently not. In fact, nearly half of all states in American now legalize cannabis products in some way. Many of the other states have legislation in the works. Canada has even legalized marijuana at the national level. And the U.S. Congress has even recently legalized hemp on a national scale.
So, why does Gottlieb have such an issue with vaping? Dr. Farsalinos and many others in the vaping community are not convinced of the FDA arguments so far. Let’s see that unpublished preliminary data.
(Image courtesy of Shutterstock)
from VAPES – VAPES News Blog http://bit.ly/2IOR8cq
We’ve got Trump Tariffs on vaping products, vaping bans, flavor bans, and FDA deeming regulations with a million-dollar price tag per product. Don’t leave the War on VapIng up to the advocacy groups. TAKE ACTION NOW!
#vaping #vapes #vapescom #vape #ecig #ecigs #vapor #propyleneglycol #vapeon #vapenation #vapedaily #vapefamily #vapefam #vapelife #vapelyfe #STOP THEVAPEBAN
from VAPES http://bit.ly/2C3vWy2